Quoin Pharmaceuticals (QNRX) Stock Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.